Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
P2X3 receptor is a promising target for therapeutic intervention in cancer patients for pain management
VRT-031745
10-10-deacetylbaccatin III was found to selectively inhibit the growth of L
It is used either by injection into a vein or muscle
Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands
Nilotinib - CAS# 641571-10-0 Catalog No.:M10937-10 P2X3 receptor is a promisingNilotinib, also known as AMN107, is a small molecule tyrosine kinase inhibitor approved for the treatment of imatinib resistant chronic myelogenous leukemia. Structurally related to imatinib, it was developed based on the structure of the Abl imatinib complex to address imatinib intolerance and resistance. Nilotinib is a selective Bcr Abl kinase inhibitor that is 10 30 fold more potent than imatinib in inhibiting Bcr Abl tyrosine kinase activity and
US$ 37.91
US$ 375.00